Literature DB >> 33901863

Delta radiomics for rectal cancer response prediction using low field magnetic resonance guided radiotherapy: an external validation.

Davide Cusumano1, Luca Boldrini1, Poonam Yadav2, Gao Yu3, Bindu Musurunu2, Giuditta Chiloiro1, Antonio Piras1, Jacopo Lenkowicz1, Lorenzo Placidi1, Angela Romano1, Viola De Luca1, Claudio Votta1, Brunella Barbaro1, Maria Antonietta Gambacorta1, Michael F Bassetti2, Yingli Yang3, Luca Indovina1, Vincenzo Valentini1.   

Abstract

INTRODUCTION: A recent study performed on 16 locally advanced rectal cancer (LARC) patients treated using magnetic resonance guided radiotherapy (MRgRT) has identified two delta radiomics features as predictors of clinical complete response (cCR) after neoadjuvant radio-chemotherapy (nCRT). This study aims to validate these features (ΔLleast and Δglnu) on an external larger dataset, expanding the analysis also for pathological complete response (pCR) prediction.
METHODS: A total of 43 LARC patients were enrolled: Gross Tumour Volume (GTV) was delineated on T2/T1* MR images acquired during MRgRT and the two delta features were calculated. Receiver Operating Characteristic (ROC) curve analysis was performed on the 16 cases of the original study and the best cut-off value was identified. The performance of ΔLleast and Δglnu was evaluated at the best cut-off value.
RESULTS: On the original dataset of 16 patients, ΔLleast reported an AUC of 0.81 for cCR and 0.93 for pCR, while Δglnu 0.72 and 0.54 respectively. The best cut-off values of ΔLleast was 0.73 for both outcomes, while Δglnu reported 0.54 for cCR and 0.93 for pCR. At the external validation, ΔLleast showed an accuracy of 81% for cCR and 79% for pCR, while Δglnu reported 63% for cCR and 40% for pCR.
CONCLUSION: The accuracy of ΔLleast in predicting cCR and pCR is significantly higher than those obtained considering Δglnu, but inferior if compared with other image-based biomarker, such as the early-regression index. Studies with larger cohorts of patients are recommended to further investigate the role of delta radiomic features in MRgRT.
Copyright © 2021 Associazione Italiana di Fisica Medica. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Delta radiomics; Predictive modelling; Radiomics; Rectal CANCER; Response prediction

Year:  2021        PMID: 33901863     DOI: 10.1016/j.ejmp.2021.03.038

Source DB:  PubMed          Journal:  Phys Med        ISSN: 1120-1797            Impact factor:   2.685


  8 in total

1.  Delta radiomics: a systematic review.

Authors:  Valerio Nardone; Alfonso Reginelli; Roberta Grassi; Luca Boldrini; Giovanna Vacca; Emma D'Ippolito; Salvatore Annunziata; Alessandra Farchione; Maria Paola Belfiore; Isacco Desideri; Salvatore Cappabianca
Journal:  Radiol Med       Date:  2021-12-04       Impact factor: 3.469

Review 2.  Magnetic resonance linear accelerator technology and adaptive radiation therapy: An overview for clinicians.

Authors:  William A Hall; Eric Paulson; X Allen Li; Beth Erickson; Christopher Schultz; Alison Tree; Musaddiq Awan; Daniel A Low; Brigid A McDonald; Travis Salzillo; Carri K Glide-Hurst; Amar U Kishan; Clifton D Fuller
Journal:  CA Cancer J Clin       Date:  2021-11-18       Impact factor: 508.702

Review 3.  Review of Radiomics- and Dosiomics-based Predicting Models for Rectal Cancer.

Authors:  Yun Qin; Li-Hua Zhu; Wei Zhao; Jun-Jie Wang; Hao Wang
Journal:  Front Oncol       Date:  2022-08-09       Impact factor: 5.738

4.  Ability of Delta Radiomics to Predict a Complete Pathological Response in Patients with Loco-Regional Rectal Cancer Addressed to Neoadjuvant Chemo-Radiation and Surgery.

Authors:  Valerio Nardone; Alfonso Reginelli; Roberta Grassi; Giovanna Vacca; Giuliana Giacobbe; Antonio Angrisani; Alfredo Clemente; Ginevra Danti; Pierpaolo Correale; Salvatore Francesco Carbone; Luigi Pirtoli; Lorenzo Bianchi; Angelo Vanzulli; Cesare Guida; Roberto Grassi; Salvatore Cappabianca
Journal:  Cancers (Basel)       Date:  2022-06-18       Impact factor: 6.575

5.  THUNDER 2: THeragnostic Utilities for Neoplastic DisEases of the Rectum by MRI guided radiotherapy.

Authors:  Giuditta Chiloiro; Davide Cusumano; Luca Boldrini; Angela Romano; Lorenzo Placidi; Matteo Nardini; Elisa Meldolesi; Brunella Barbaro; Claudio Coco; Antonio Crucitti; Roberto Persiani; Lucio Petruzziello; Riccardo Ricci; Lisa Salvatore; Luigi Sofo; Sergio Alfieri; Riccardo Manfredi; Vincenzo Valentini; Maria Antonietta Gambacorta
Journal:  BMC Cancer       Date:  2022-01-15       Impact factor: 4.430

6.  A Predictive Model of 2yDFS During MR-Guided RT Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer Patients.

Authors:  Giuditta Chiloiro; Luca Boldrini; Francesco Preziosi; Davide Cusumano; Poonam Yadav; Angela Romano; Lorenzo Placidi; Jacopo Lenkowicz; Nicola Dinapoli; Michael F Bassetti; Maria Antonietta Gambacorta; Vincenzo Valentini
Journal:  Front Oncol       Date:  2022-02-24       Impact factor: 6.244

7.  Global status of research on radiotherapy for rectal cancer: A bibliometric and visual analysis.

Authors:  Yafei Xiao; Mengyuan Qiu; Wanting Huang; Shaowen Hu; Cong Tan; Fangmei Nan; Xiaowei Jiang; Dapeng Wu; Mengmeng Li; Quanying Li; Changjiang Qin
Journal:  Front Public Health       Date:  2022-08-08

8.  Fractal-Based Radiomic Approach to Tailor the Chemotherapy Treatment in Rectal Cancer: A Generating Hypothesis Study.

Authors:  Carmela Di Dio; Giuditta Chiloiro; Davide Cusumano; Francesco Catucci; Luca Boldrini; Angela Romano; Elisa Meldolesi; Fabio Marazzi; Barbara Corvari; Brunella Barbaro; Riccardo Manfredi; Vincenzo Valentini; Maria Antonietta Gambacorta
Journal:  Front Oncol       Date:  2021-12-09       Impact factor: 6.244

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.